Other Chiral Phase
Regis manufactures various Pirkle CSPs. These can separate a wide variety of enantiomers in numerous compound groups. Examples include:
• Aryl Propionic Acid Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Agricultural Compounds
• Natural Products
• Many Pharmaceuticals
Lot more data on enantiomer separations can be found on our website at www.registech.com/chiral-applications.
The ULMO chiral stationary phase was developed by Austrian researchers Dr. Georg Uray, Dr. Wolfgang Linder, and Dr. Nobert Maier. The ULMO CSP is based on a 3,5-dintrobenzoyl derivative of diphenylethylenediamine. This CSP has a general ability to separate the enantiomers of many racemate classes and is particularly good at separating the enantiomers of aryl carbinols.
3,5-dinitrobenzoyl Phenylglycine, a π-acceptor chiral phase, is based on 3,5-dinitrobenzoyl phenylglycine, covalently bonded to 5 µm aminopropyl silica. Phenylglycine columns are available in both L- and D- configurations. This CSP resolves a wide variety of compounds containing π-basic groups, including aryl-substituted cyclic sulfoxides, bi-ß-naphthol and its analogs, α-indanol and α-tetralol analogs, and arylsubstituted hydantoins. This CSP matches USP L36.
The π-acceptor leucine CSP is based on 3,5-dinitrobenzoyl leucine, covalently bonded to 5 µm aminopropyl silica. Columns derived from either L- or D- leucine are available. This phase demonstrates enhanced enantioselectivities for several classes of compounds, including benzodiazapines.
β-Gem1 π-acceptor CSP
β-Gem1 is a π-acceptor chiral stationary phase and is prepared by covalently bonding N-3, 5-dinitrobenzoyl-3-amino- 3-phenyl-2-(1,1- dimethylethyl)-propanoate, to 5 µm silica through an ester linkage. In many cases, this chiral phase considerably outperforms its widely used analog, phenylglycine. It can separate anilide derivatives of chiral carboxylic acids, including nonsteroidal anti-inflammatory agents. Available in (R,R) and (S,S) forms to invert elution order if desired. Selector/Phase Type is N-3, 5-dinitrobenzoyl-3-amino- 3-phenyl-2-(1,1-dimethylethyl)-propanoate.
α-Burke 2 phase is derived from dimethyl N-3,5-dinitro-benzoyl--amino2,2-dimethyl- 4-pentenyl phosphonate covalently bound to 5 μm silica. This π-acceptor chiral stationary phase is particularly valuable in the HPLC separation of ß-blocker enantiomers, an important class of cardiovascular drugs whose enantiomers often exhibit differing pharmacological activities. The a-Burke 2 has been specifically designed to separate the enantiomers of ß-blockers withoutchemical derivatization. In addition, it also resolves the enantiomers of many compounds separated on π-acceptor Pirkle type chiral stationary phases.
Prikle 1-J CSP
he Pirkle 1-J column is the latest in a series of CSPs from the research laboratories of Professor Pirkle. This new CSP contains an unusual ß-lactam structure which significantly alters its molecular recognition properties. The Pirkle 1-J is useful for the direct separation of underivatized ß-blocker enantiomers. It can also be used for the separation of the enantiomers of arylpropionic acid NSAIDs as well as other drugs.
The innovative DACH-DNB CSP was designed by Italian chemist, Professor Francesco Gasparrini, at Sapienza Universita di Roma. The DACH-DNB CSP, which contains the 3,5-dinitrobenzoyl derivative of 1,2-diaminocyclohexane, has been found to resolve a broad range of racemate classes including amides, alcohols, esters, ketones, acids, sulfoxides, phosphine oxides, selenoxides, phosphonates, thiophosphineoxide, phosphineselenide, phosphine-borane, beta-lactams, organometallics, atropisomers, and heterocycles.